JP drafts for public comments, March 1, 2023 - May 31, 2023
New monographs
- Aripiprazole (008-2303eng.pdf)
- Febuxostat (009-2303eng.pdf)
- Febuxostat Tablets (010-2303eng.pdf)
- Gefitinib Tablets (011-2303eng.pdf)
- Goserelin Acetate (012-2303eng.pdf)
- Lornoxicam (013-2303eng.pdf)
- Lornoxicam Tablets (014-2303eng.pdf)
- Oxaliplatin (015-2303eng.pdf)
- Oxaliplatin Injection (016-2303eng.pdf)
- Tolvaptan (017-2303eng.pdf)
- Tolvaptan Tablets (018-2303eng.pdf)
New monographs (Crude drug)
- Shin’iseihaito Extract (019-2303eng.pdf)
Ultraviolet-visible reference spectra
- Aripiprazole (020-2303eng.pdf)
- Febuxostat (021-2303eng.pdf)
- Lornoxicam (022-2303eng.pdf)
- Oxaliplatin (023-2303eng.pdf)
- Tolvaptan (024-2303eng.pdf)
Infrared reference spectra
- Aripiprazole (025-2303eng.pdf)
- Febuxostat (026-2303eng.pdf)
- Lornoxicam (027-2303eng.pdf)
- Oxaliplatin (028-2303eng.pdf)
- Tolvaptan (029-2303eng.pdf)
To send the comment on these drafts, the guidance is as follows:
- Download the form for comments in Word format
- Fill in the form
- Prepare and attach the supportive data that scientifically validate the comment when appropriate
- Send it to the email address: JPdraft-eng●pmda.go.jp
Note:
For the purpose of security, this email address is partly incorrect. Please replace ● with @ when sending an email.
Related Information
Note:
The information submitted with the comments may be released to the public whenever necessary (except the individual name, organization, address, telephone & fax numbers and e-mail address or the attached supportive data).
Your comments will be considered for the preparation of JP final drafts, but no individual response will be made to each comment.